Perspective Therapeutics [212Pb]VMT-α-NET cohort safety, efficacy data set for ENA Symposium poster session

PUBT · 1d ago
Perspective Therapeutics [212Pb]VMT-α-NET cohort safety, efficacy data set for ENA Symposium poster session
  • Perspective Therapeutics flagged updated data from its [212Pb]VMT-α-NET study for presentation at the EORTC-NCI-AACR Symposium in November 2026.
  • Interim results were already presented at the 2026 ASCO meeting, based on an April 17, 2026 data cut-off.
  • The program showed early signs of clinical activity with an initial safety profile in advanced SSTR2-positive neuroendocrine tumors, without prior radiopharmaceutical therapy.
  • The trial remains ongoing as a multi-center, open-label dose-escalation and dose-expansion study in unresectable or metastatic disease.
  • Additional readouts are expected as enrollment progresses, including pending efficacy updates from later cohorts in 2026 and 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perspective Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609110600PRIMZONEFULLFEED9825032) on September 11, 2026, and is solely responsible for the information contained therein.